162 related articles for article (PubMed ID: 29233917)
1. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.
Yang J; Liu Z; Liu H; He J; Yang J; Lin P; Wang Q; Du J; Ma W; Yin Z; Davis E; Orlowski RZ; Hou J; Yi Q
Sci Signal; 2017 Dec; 10(509):. PubMed ID: 29233917
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.
Yang J; He J; Wang J; Cao Y; Ling J; Qian J; Lu Y; Li H; Zheng Y; Lan Y; Hong S; Matthews J; Starbuck MW; Navone NM; Orlowski RZ; Lin P; Kwak LW; Yi Q
Leukemia; 2012 Sep; 26(9):2114-23. PubMed ID: 22425892
[TBL] [Abstract][Full Text] [Related]
3. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
He J; Liu Z; Zheng Y; Qian J; Li H; Lu Y; Xu J; Hong B; Zhang M; Lin P; Cai Z; Orlowski RZ; Kwak LW; Yi Q; Yang J
Cancer Res; 2012 Dec; 72(24):6393-402. PubMed ID: 23066034
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal immunoglobulins promote bone loss in multiple myeloma.
Westhrin M; Kovcic V; Zhang Z; Moen SH; Nedal TMV; Bondt A; Holst S; Misund K; Buene G; Sundan A; Waage A; Slørdahl TS; Wuhrer M; Standal T
Blood; 2020 Dec; 136(23):2656-2666. PubMed ID: 32575115
[TBL] [Abstract][Full Text] [Related]
5. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein impairs immune response of CD8
Jiang J; Peng Z; Wang J; Chen M; Wan Y; Huang H; Liu Z; Wang J; Hou J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37844994
[TBL] [Abstract][Full Text] [Related]
7. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
11. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
12. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors.
Lin J; Lee D; Choi Y; Lee SY
Sci Signal; 2015 Jun; 8(379):ra54. PubMed ID: 26038599
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
[TBL] [Abstract][Full Text] [Related]
14. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
15. [Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
[TBL] [Abstract][Full Text] [Related]
16. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.
Yang J; Wezeman M; Zhang X; Lin P; Wang M; Qian J; Wan B; Kwak LW; Yu L; Yi Q
Cancer Cell; 2007 Sep; 12(3):252-65. PubMed ID: 17785206
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.
Mahajan N; Bahl A; Dhawan V
Int J Cardiol; 2010 Jul; 142(3):273-8. PubMed ID: 19201044
[TBL] [Abstract][Full Text] [Related]
18. MAPK p38: alternative and nonstressful in T cells.
Rudd CE
Nat Immunol; 2005 Apr; 6(4):368-70. PubMed ID: 15785766
[No Abstract] [Full Text] [Related]
19. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction.
Seo SK; Lee HC; Woo SH; Jin HO; Yoo DH; Lee SJ; An S; Choe TB; Park MJ; Hong SI; Park IC; Rhee CH
Apoptosis; 2007 Jan; 12(1):195-209. PubMed ID: 17136320
[TBL] [Abstract][Full Text] [Related]
20. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
